EPIEN Medical, Inc
EPIEN Medical continues to develop its innovative, patented platform for nonbiologic, therapeutic treatments to restore and regenerate impaired epidermal and dermal tissue. EPIEN Medical, Inc. (EMI) is a privately held biomedical company headquartered in St. Paul, Minnesota, USA. The Company is focused on the global health challenges of restoring impaired skin (the bodies largest organ), including both epidermal and dermal layers. This is accomplished through a groundbreaking debridement technology based around a proprietary chemical desiccation process. Our technology platform is called Desiccation Shock Debridement Technology (“DSD”). This proprietary debridement technology is based on a cellular and a molecular process. The products are intended for use by healthcare professionals in the management of oral disease, acute and chronic wounds and burns as well veterinary care.
Products containing our patented HYBENX® technology are cleared as Class I medical devices in the European Union and Canada. The US FDA has also reviewed HYBENX® Root Canal Cleanser and found it substantially equivalent on K123538. The Company currently has products for sale throughout Europe, the Middle East, and Africa, as well as Canada and Australia through contracted distributor relationships. EPIEN also manufactures the pre-amendment drug Debacterol®, which is marketed to dentists in the United States as a unique treatment for Aphthous ulcers (canker sores).
EPIEN’s research and development activity is focused on expanding applications for these and similar products to treat a variety of topical skin infections ranging from ailments such as athlete’s foot to more severe conditions such as periodontal diseases and chronic non-healing wounds.